Investigational drug · Phase 3
RC28-E
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetic Macular Edema (DME), wAMD.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "RC28-E"
First trial start
2026
Oct 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RC28-E", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Macular Edema (DME)
- wAMD
Approved drugs for the same conditions: Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "RC28-E" as an intervention, largest first.
- Efficacy and Safety of RC28-E Versus AfliberceptPivotal-lookingStatus unknown
RemeGen Co., Ltd.Industry
NCT05727397 · 432 participants (planned) · Start Mar 14, 2023 · Primary completion Nov 29, 2025
Drug: RC28-E; Aflibercept · For: Wet Age-related Macular Degeneration
Sites: Beijing, China
- IIIb Trial for RC28-E Injection in Participants With DME and wAMDPivotal-lookingNot yet recruiting
RemeGen Co., Ltd.Industry
NCT07936487 · 350 participants (planned) · Start Oct 30, 2026 · Primary completion Dec 1, 2028
Drug: RC28-E · For: Diabetic Macular Edema (DME); wAMD
Sites: Beijing, China
- Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular EdemaPivotal-lookingStatus unknown
RemeGen Co., Ltd.Industry
NCT05885503 · 316 participants (planned) · Start Jun 8, 2023 · Primary completion Jun 2026
Drug: RC-28E; Aflibercept · For: Diabetic Macular Edema
Sites: Beijing, China
- Evaluation of RC28-E Injection in Diabetic Macular EdemaPivotal-lookingCompleted
RemeGen Co., Ltd.Industry
NCT04782115 · 156 participants · Start Mar 17, 2021 · Primary completion Jul 31, 2023
Drug: intravitreal injection of RC28-E; Conbercept · For: Diabetic Macular Edema
Sites: Hefei, China; Beijing, China; Chongqing, China · 37 sites in all
- Evaluation of RC28-E Injection in Diabetic RetinopathyPivotal-lookingStatus unknown
RemeGen Co., Ltd.Industry
NCT04782128 · 120 participants (planned) · Start May 25, 2021 · Primary completion May 2024
Drug: RC28-E injection · For: Diabetic Retinopathy
Sites: Beijing, China
RemeGen Co., Ltd.Industry
NCT04270669 · 37 participants · Start Apr 15, 2020 · Primary completion Oct 29, 2021
Drug: intravitreal injection of RC28-E 0.5mg; intravitreal injection of RC28-E 1.0mg and 1 more · For: Wet Age-Related Macular Degeneration
Sites: Beijing, China
RemeGen Co., Ltd.Industry
NCT03777254 · 12 participants · Start Jan 7, 2019 · Primary completion Aug 20, 2019
Drug: RC28-E · For: Neovascular Age-related Macular Degeneration
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Simultaneous inhibition of fibroblast growth factor-2 and vascular endothelial growth factor-a with RC28-E in diabetic macular edema: a phase 2 randomised trial.
Zhang W, Cheng S, Gu X, et al. · Br J Ophthalmol 2025
- Safety and Efficacy of Multiple Escalating Doses of RC28-E for Neovascular Age-Related Macular Degeneration: A Phase 1b Trial.
Lu Y, Yu X, Chen Y, et al. · Ophthalmol Ther 2024
- In vivo characterization of RC28-E, a fusion protein targeting VEGF and bFGF: Pharmacokinetics and ocular distribution in primates.
Jiang J, Wang L, Kou X, et al. · Exp Eye Res 2020
- Pharmacology Study of the Multiple Angiogenesis Inhibitor RC28-E on Anti-Fibrosis in a Chemically Induced Lung Injury Model.
Kou X, Sun Y, Li S, et al. · Biomolecules 2019
- Protective effects of a novel drug RC28-E blocking both VEGF and FGF2 on early diabetic rat retina.
Yang QH, Zhang Y, Jiang J, et al. · Int J Ophthalmol 2018
Also in development for Diabetic Macular Edema (DME)
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- EYP-1901Phase 34 trials
EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- OLN324Phase 34 trials
Ollin Biosciences, Inc. · Diabetic Macular Edema (DME), Wet Age Related Macular Degeneration, Wet Age-related Macular Degeneration
- RemigromigEYE103, RestoretPhase 33 trials
EyeBiotech Ltd. · Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
- BAT5906Phase 32 trials
Bio-Thera Solutions · Diabetic Macular Edema (DME), Neovascular (Wet) Age-related Macular Degeneration
- Tabirafusp tedromerKSI-501Phase 32 trials
Kodiak Sciences Inc · Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration
- BGE-102Phase 22 trials
BioAge Labs, Inc. · Diabetic Macular Edema (DME), Obesity and Cardiovascular Risk
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.